• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors.
【24h】

Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors.

机译：与依替非巴肽靶向较高风险的急性冠脉综合征患者相关的出血：发生率和多因素危险因素。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objective of this study was to determine the safety of the glycoprotein IIb/IIIa receptor inhibitor eptifibatide in patients at high risk for adverse clinical outcomes and to determine risk factors for eptifibatide-associated bleeding. Consecutive patients (n = 175) who presented with an acute coronary syndrome and who were at high risk for adverse clinical outcomes were prospectively observed for eptifibatide-associated bleeding, which was classified according to Thrombolysis in Myocardial Infarction (TIMI) and Global Use of Strategies to Open Occluded arteries (GUSTO) criteria. High risk was defined as unstable angina or non-Q-wave myocardial infarction with at least one of the following: left ventricular ejection fraction < 40%, diabetes mellitus, ST segment depression or transient ST segment elevation, serum [troponin I] > 2.5 ng/mL, and recurrent angina symptoms after initiation of conventional antianginal therapy. Bleeding incidences in the patients in this study were compared with those in the 4722 eptifibatide-treated patients in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Compared to PURSUIT patients, the population in this study was similar in age but had a higher proportion of females, African Americans, hypertension, diabetes, prior myocardial infarction, heart failure, and revascularization. Bleeding incidences in this study's patients were similar to or lower than those in the PURSUIT population: TIMI major 1.1% versus 10.8%, TAMI minor 12.6% versus 13.1%, GUSTO severe 1.7% versus 1.5%, GUSTO moderate 3.9% versus 11.3%, and GUSTO mild 19.7% versus 26.1%. Renal dysfunction was an independent risk factor for TIMI (odds ratio = 9.1 ([95% CI= 1.6-52.5]) and GUSTO (odds ratio = 6.1 [95% CI = 1.2-30.0]) bleeding. In conclusion, despite being at higher risk for adverse outcomes, patients administered eptifibatide according to this study's institutional guidelines had comparable or lower bleeding rates than in the PURSUIT trial. Renal dysfunction is an independent risk factor for eptifibatide-induced bleeding.
机译：这项研究的目的是确定糖蛋白IIb / IIIa受体抑制剂依替非巴肽在具有不良临床结局的高风险患者中的安全性，并确定与依替非巴肽相关的出血的危险因素。前瞻性观察到连续性患者（n = 175）患有急性冠状动脉综合征并具有不良临床结果的高风险，依替巴肽相关的出血根据心肌梗塞溶栓（TIMI）和总体使用策略进行分类打开闭塞动脉（GUSTO）标准。高危定义为不稳定型心绞痛或非Q波心肌梗死，且至少具有以下一项：左心室射血分数<40％，糖尿病，ST段压低或短暂性ST段抬高，血清[肌钙蛋白I]> 2.5 ng / mL，以及常规抗心绞痛治疗开始后复发的心绞痛症状。将本研究中患者的出血发生率与不稳定型心绞痛的血小板糖蛋白IIb / IIIa：使用整联蛋白疗法（PURSUIT）抑制受体的4722位依替巴肽治疗的患者的出血发生率进行了比较。与PURSUIT患者相比，本研究的人群年龄相似，但女性，非裔美国人，高血压，糖尿病，既往心肌梗塞，心力衰竭和血运重建的比例更高。该研究患者的出血发生率与PURSUIT人群中的出血发生率相似或更低：TIMI重度1.1％对10.8％，TAMI重度12.6％对13.1％，GUSTO重度1.7％对1.5％，GUSTO中度3.9％对11.3％，和GUSTO的比率为26.1％，为19.7％。肾功能不全是TIMI（比值= 9.1（[95％CI = 1.6-52.5]）和GUSTO（比值= 6.1 [95％CI = 1.2-30.0]）出血的独立危险因素。不良后果的风险较高，根据本研究的机构指南给予依替巴肽治疗的患者的出血率与PURSUIT试验相近或更低，而肾功能不全是依替巴肽引起的出血的独立危险因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号